ALCJ.PA
Crossject Société Anonyme [ALCJ.PA] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
ALCJ.PA Stock Summary
Top 10 Correlated ETFs
ALCJ.PA
Top 10 Correlated Stocks
ALCJ.PA
In the News
ALCJ.PA Financial details
Company Rating
Neutral
Market Cap
73.25M
Income
-19.62M
Revenue
12.8M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
110
Optionable
No
Shortable
Yes
Earnings
19 Mar 2024
P/E
-18.26
Forward P/E
-
PEG
-2.36
P/S
212.62
P/B
75.87
P/C
-
P/FCF
-17.11
Quick Ratio
1.45
Current Ratio
2.58
Debt / Equity
-
LT Debt / Equity
-7.73
-
-
EPS (TTM)
-0.55
EPS next Y
-
EPS next Q
-
EPS this Y
-25.81%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-8.57%
Revenue last 5Y
117.54%
Revenue Q/Q
182.41%
EPS Q/Q
-8.33%
-
-
-
-
SMA20
-33.33%
SMA50
-60%
SMA100
-50%
Inst Own
-
Inst Trans
-
ROA
-34%
ROE
798%
ROC
-0.48%
Gross Margin
-126%
Oper. Margin
-1393%
Profit Margin
-1169%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.828-5.96
52W High
-58.8%
52W Low
+106%
RSI
31
Rel Volume
0.41
Avg Volume
118.09K
Volume
48.32K
Perf Week
-5.07%
Perf Month
-40.12%
Perf Quarter
-46.77%
Perf Half Y
-46.77%
-
-
-
-
Beta
0.844
-
-
Volatility
0.07%, 0.63%
Prev Close
0.98%
Price
2.06
Change
-0.48%
ALCJ.PA Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.02 | 0.2 | 0.04 | 0.03 | 0 | |
| Net income per share | -0.36 | -0.41 | -0.42 | -0.31 | 0 | |
| Operating cash flow per share | -0.27 | -0.23 | -0.23 | -0.14 | 0 | |
| Free cash flow per share | -0.49 | -0.48 | -0.49 | -0.33 | 0 | |
| Cash per share | 0.39 | 0.35 | 0.38 | 0.21 | 0 | |
| Book value per share | 0.15 | -0.05 | -0.24 | 0.06 | 0 | |
| Tangible book value per share | -0.16 | -0.36 | -0.56 | -0.22 | 0 | |
| Share holders equity per share | 0.15 | -0.05 | -0.24 | 0.06 | 0 | |
| Interest debt per share | 0.53 | 0.9 | 0.93 | 0.4 | 0 | |
| Market cap | 46.3M | 73.09M | 74.12M | 119.81M | 0 | |
| Enterprise value | 48.99M | 86.02M | 87.62M | 126.16M | 0 | |
| P/E ratio | -6.45 | -7.42 | -6.86 | -10.74 | 0 | |
| Price to sales ratio | 92.59 | 15.09 | 81.27 | 125.58 | 0 | |
| POCF ratio | -8.4 | -13.38 | -12.18 | -23.58 | 0 | |
| PFCF ratio | -4.67 | -6.32 | -5.78 | -10.1 | 0 | |
| P/B Ratio | 15.36 | -64.67 | -12.06 | 59.28 | 0 | |
| PTB ratio | 15.36 | -64.67 | -12.06 | 59.28 | 0 | |
| EV to sales | 97.99 | 17.76 | 96.07 | 132.24 | 0 | |
| Enterprise value over EBITDA | -8.95 | -12.39 | -11.61 | -15.84 | 0 | |
| EV to operating cash flow | -8.89 | -15.75 | -14.4 | -24.83 | 0 | |
| EV to free cash flow | -4.94 | -7.44 | -6.84 | -10.64 | 0 | |
| Earnings yield | -0.15 | -0.13 | -0.15 | -0.09 | 0 | |
| Free cash flow yield | -0.21 | -0.16 | -0.17 | -0.1 | 0 | |
| Debt to equity | 3.48 | -18.64 | -3.8 | 6.99 | 0 | |
| Debt to assets | 0.43 | 0.63 | 0.74 | 0.43 | 0 | |
| Net debt to EBITDA | -0.49 | -1.86 | -1.79 | -0.8 | 0 | |
| Current ratio | 2.26 | 2.01 | 2.1 | 1.41 | 0 | |
| Interest coverage | -92.52 | -26.69 | -14.25 | -47.75 | -24.74 | |
| Income quality | 0.77 | 0.55 | 0.56 | 0.46 | 0 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 9.3 | 1.2 | 6.64 | 7.77 | 0 | |
| Intangibles to total assets | 0.26 | 0.22 | 0.29 | 0.33 | 0 | |
| Capex to operating cash flow | 0.8 | 1.12 | 1.11 | 1.33 | 0 | |
| Capex to revenue | -8.8 | -1.26 | -7.38 | -7.1 | 0 | |
| Capex to depreciation | -1.21 | -1.54 | -1.5 | -1.29 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 1.1 | 0.66 | 1.49 | 0.62 | 0 | |
| ROIC | -0.48 | -0.4 | -0.53 | -0.62 | 0 | |
| Return on tangible assets | -0.39 | -0.38 | -0.48 | -0.5 | 0 | |
| Graham Net | -0.56 | -0.82 | -0.96 | -0.52 | 0 | |
| Working capital | 6.57M | 9.21M | 7.08M | 4.04M | 0 | |
| Tangible asset value | -3.24M | -8.67M | -14.62M | -8.01M | 0 | |
| Net current asset value | -9.71M | -16.41M | -23.52M | -16.34M | 0 | |
| Invested capital | 3.48 | -18.64 | -3.8 | 6.99 | 0 | |
| Average receivables | 1.01M | 5.06M | 4.88M | 2.42M | 0 | |
| Average payables | 2.24M | 2.13M | 2.16M | 2.74M | 0 | |
| Average inventory | 1.52M | 1.65M | 1.73M | 2.1M | 0 | |
| Days sales outstanding | 1.48K | 609.3 | 666.77 | 1.21K | 0 | |
| Days payables outstanding | 67.2 | 217.64 | 59.77 | 86.6 | 0 | |
| Days of inventory on hand | 53.21 | 165.63 | 50.63 | 62.46 | 0 | |
| Receivables turnover | 0.25 | 0.6 | 0.55 | 0.3 | 0 | |
| Payables turnover | 5.43 | 1.68 | 6.11 | 4.21 | 0 | |
| Inventory turnover | 6.86 | 2.2 | 7.21 | 5.84 | 0 | |
| ROE | -2.38 | 8.71 | 1.76 | -5.52 | 0 | |
| Capex per share | -0.22 | -0.26 | -0.26 | -0.19 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
| Metric | History | 2021-12-31 | 2022-06-30 | 2022-12-31 | 2023-06-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.02 | 0.01 | 0.01 | 0.08 | 0 | |
| Net income per share | -0.2 | -0.17 | -0.15 | -0.12 | 0 | |
| Operating cash flow per share | -0.13 | -0.1 | -0.05 | -0.11 | 0 | |
| Free cash flow per share | -0.28 | -0.18 | -0.16 | -0.24 | 0 | |
| Cash per share | 0.38 | 0.17 | 0.21 | 0.15 | 0 | |
| Book value per share | -0.23 | 0.07 | 0.06 | -0.05 | 0 | |
| Tangible book value per share | -0.56 | -0.18 | -0.22 | -0.32 | 0 | |
| Share holders equity per share | -0.23 | 0.07 | 0.06 | -0.05 | 0 | |
| Interest debt per share | 0.91 | 0.32 | 0.39 | 0.56 | 0 | |
| Market cap | 74.62M | 110.05M | 119.81M | 151.1M | 0 | |
| Enterprise value | 88.11M | 115.39M | 126.16M | 165.92M | 0 | |
| P/E ratio | -3.48 | -4.68 | -5.67 | -8.28 | 0 | |
| Price to sales ratio | 149.31 | 242.4 | 239.61 | 48.77 | 0 | |
| POCF ratio | -21.6 | -32.68 | -69.94 | -35.85 | 0 | |
| PFCF ratio | -10.24 | -17.74 | -21.19 | -17.38 | 0 | |
| P/B Ratio | -12.14 | 44.11 | 59.28 | -81.32 | 0 | |
| PTB ratio | -12.14 | 44.11 | 59.28 | -81.32 | 0 | |
| EV to sales | 176.32 | 254.16 | 252.32 | 53.56 | 0 | |
| Enterprise value over EBITDA | -24.44 | -26.73 | -34.58 | -33.8 | 0 | |
| EV to operating cash flow | -25.51 | -34.27 | -73.65 | -39.36 | 0 | |
| EV to free cash flow | -12.1 | -18.6 | -22.31 | -19.08 | 0 | |
| Earnings yield | -0.07 | -0.05 | -0.04 | -0.03 | 0 | |
| Free cash flow yield | -0.1 | -0.06 | -0.05 | -0.06 | 0 | |
| Debt to equity | -3.8 | 4.38 | 6.99 | -10.88 | 0 | |
| Debt to assets | 0.74 | 0.4 | 0.43 | 0.6 | 0 | |
| Net debt to EBITDA | -3.74 | -1.24 | -1.74 | -3.02 | 0 | |
| Current ratio | 2.1 | 1.56 | 1.41 | 1.09 | 0 | |
| Interest coverage | -9.62 | -57.49 | -40.09 | -31.61 | 3.02 | |
| Income quality | 0.64 | 0.57 | 0.32 | 0.92 | 0 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 8.15 | 0 | 10.25 | 0.93 | 0 | |
| Intangibles to total assets | 0.29 | 0.34 | 0.33 | 0.32 | 0 | |
| Capex to operating cash flow | 1.11 | 0.84 | 2.3 | 1.06 | 0 | |
| Capex to revenue | -7.66 | -6.25 | -7.88 | -1.45 | 0 | |
| Capex to depreciation | -1.82 | -1.05 | -1.54 | -1.32 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 1.04 | 0.52 | 0.43 | 0.38 | 0 | |
| ROIC | -0.25 | -0.38 | -0.29 | -0.31 | 0 | |
| Return on tangible assets | -0.24 | -0.32 | -0.24 | -0.2 | 0 | |
| Graham Net | -0.95 | -0.47 | -0.52 | -0.67 | 0 | |
| Working capital | 7.08M | 3.55M | 4.04M | 1.16M | 0 | |
| Tangible asset value | -14.62M | -6.23M | -8.01M | -11.94M | 0 | |
| Net current asset value | -23.52M | -14.61M | -16.34M | -21.4M | 0 | |
| Invested capital | -3.8 | 4.38 | 6.99 | -10.88 | 0 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 0 | 0 | 0 | 0 | 0 | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 300.04 | 408.96 | 571.5 | 143.86 | 0 | |
| Days payables outstanding | 29.99 | 23 | 43.05 | 31.96 | 0 | |
| Days of inventory on hand | 25.4 | 23.52 | 31.05 | 25.11 | 0 | |
| Receivables turnover | 0.3 | 0.22 | 0.16 | 0.63 | 0 | |
| Payables turnover | 3 | 3.91 | 2.09 | 2.82 | 0 | |
| Inventory turnover | 3.54 | 3.83 | 2.9 | 3.58 | 0 | |
| ROE | 0.87 | -2.35 | -2.61 | 2.46 | 0 | |
| Capex per share | -0.15 | -0.08 | -0.11 | -0.12 | 0 |
ALCJ.PA Frequently Asked Questions
What is Crossject Société Anonyme stock symbol ?
Crossject Société Anonyme is a FR stock and trading under the symbol ALCJ.PA
What is Crossject Société Anonyme stock quote today ?
Crossject Société Anonyme stock price is $2.06 today.
Is Crossject Société Anonyme stock public?
Yes, Crossject Société Anonyme is a publicly traded company.
Company Profile
- Volume Average 118.09K
- Market Capitalization 73.25M
- Employee 110
- CEO Mr. Patrick Alexandre
- Headquarters Dijon,FR
- IPO Date 2014-02-20
-
Website
https://www.crossject.com 
Crossject Société Anonyme develops needle-free injection systems. The company develops ZENEO, a needle-free, prefilled, and single-use auto-injector. Its clinical stage drugs comprise Sumatriptan, which is used for of treatment migraines and cluster headaches; Adrenaline for treating anaphylactic shock; Hydrocortisone that is used for treatment of acute adrenal crisis; Midazolam for treating epileptic seizure; Naloxone used for treatment of overdose; Apomorphine, for treating temporary paralysis in parkinson's disease; Methotrexate used for treatment of rheumatoid arthritis; and Terbutaline, for treating severe asthma crisis. The company was founded in 1997 and is based in Dijon, France.
